FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2547720907> ?p ?o ?g. }

• W2547720907 abstract "Generalized tonic-clonic seizures (GTCSs) are the main risk factor for sudden unexpected death in epilepsy (SUDEP). Experimental and clinical data strongly suggest that the majority of SUDEP results from a postictal respiratory dysfunction progressing to terminal apnea. Postictal apnea could partly derive from a seizure-induced massive release of endogenous opioids. The main objective of this study is to evaluate the efficacy of an opioid antagonist, naloxone, administered in the immediate aftermath of a GTCS, in reducing the severity of the postictal central respiratory dysfunction. The Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients with Epilepsy (ENALEPSY) study is a multicenter, double-blind, randomized, placebo-controlled trial conducted in patients with drug-resistant focal epilepsy who are undergoing long-term video-electroencephalogram (EEG) monitoring (LTM) in an epilepsy monitoring unit (EMU). We plan to randomize 166 patients (1:1) to receive intravenous naloxone (0.4 mg) or placebo in the immediate aftermath of a GTCS. Because inclusion in the study needs to take place prior to the occurrence of the GTCS, and because such occurrence is observed in about one-fourth of patients undergoing LTM, we plan to include a maximum of 700 patients upon admission in the EMU. The primary endpoint will be the proportion of patients whose oxygen saturation is <90 % between 1 and 3 min after the end of a GTCS. Secondary outcomes will include the following: the proportion of patients who show postictal apnea, the occurrence and duration of postictal generalized EEG suppression, the total duration of the postictal coma, postictal pain, and the number of patients who have a second GTCS within 120 min after the intravenous injection. The demonstration of naloxone’s efficacy on the severity of postictal hypoxemia will have two primary consequences. First, naloxone would be the first and only therapeutic approach that could be delivered immediately to reverse postictal apnea. Second, demonstration that an opioid antagonist can effectively reduce postictal apnea would pave the way for an assessment of a preventive therapy for SUDEP targeting the same pathophysiological pathway using oral administration of naltrexone. ClinicalTrials.gov identifier: NCT02332447 . Registered on 5 January 2015." @default.
• W2547720907 created "2016-11-11" @default.
• W2547720907 creator A5018669927 @default.
• W2547720907 creator A5023594320 @default.
• W2547720907 creator A5025568086 @default.
• W2547720907 creator A5049510522 @default.
• W2547720907 creator A5051879242 @default.
• W2547720907 creator A5052601056 @default.
• W2547720907 creator A5054799901 @default.
• W2547720907 creator A5057016594 @default.
• W2547720907 creator A5061357555 @default.
• W2547720907 creator A5061673554 @default.
• W2547720907 creator A5063772828 @default.
• W2547720907 creator A5070914037 @default.
• W2547720907 creator A5076752506 @default.
• W2547720907 creator A5078556050 @default.
• W2547720907 creator A5080348265 @default.
• W2547720907 creator A5086156844 @default.
• W2547720907 creator A5086803629 @default.
• W2547720907 creator A5088572719 @default.
• W2547720907 creator A5090764517 @default.
• W2547720907 date "2016-11-03" @default.
• W2547720907 modified "2023-10-18" @default.
• W2547720907 title "Efficacy of naloxone in reducing postictal central respiratory dysfunction in patients with epilepsy: study protocol for a double-blind, randomized, placebo-controlled trial" @default.
• W2547720907 cites W1513838333 @default.
• W2547720907 cites W1543871407 @default.
• W2547720907 cites W1549808427 @default.
• W2547720907 cites W1971232865 @default.
• W2547720907 cites W1975190957 @default.
• W2547720907 cites W1996959504 @default.
• W2547720907 cites W2010654053 @default.
• W2547720907 cites W2031323283 @default.
• W2547720907 cites W2067988865 @default.
• W2547720907 cites W2102428405 @default.
• W2547720907 cites W2119181594 @default.
• W2547720907 cites W2121692105 @default.
• W2547720907 cites W2131979832 @default.
• W2547720907 cites W2133503999 @default.
• W2547720907 cites W2135415803 @default.
• W2547720907 cites W2135733572 @default.
• W2547720907 cites W2139453672 @default.
• W2547720907 cites W2157851792 @default.
• W2547720907 cites W2159300366 @default.
• W2547720907 cites W2162379283 @default.
• W2547720907 cites W2315122457 @default.
• W2547720907 cites W2437437370 @default.
• W2547720907 cites W4360894002 @default.
• W2547720907 doi "https://doi.org/10.1186/s13063-016-1653-1" @default.
• W2547720907 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5094038" @default.
• W2547720907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27809868" @default.
• W2547720907 hasPublicationYear "2016" @default.
• W2547720907 type Work @default.
• W2547720907 sameAs 2547720907 @default.
• W2547720907 citedByCount "6" @default.
• W2547720907 countsByYear W25477209072018 @default.
• W2547720907 countsByYear W25477209072019 @default.
• W2547720907 crossrefType "journal-article" @default.
• W2547720907 hasAuthorship W2547720907A5018669927 @default.
• W2547720907 hasAuthorship W2547720907A5023594320 @default.
• W2547720907 hasAuthorship W2547720907A5025568086 @default.
• W2547720907 hasAuthorship W2547720907A5049510522 @default.
• W2547720907 hasAuthorship W2547720907A5051879242 @default.
• W2547720907 hasAuthorship W2547720907A5052601056 @default.
• W2547720907 hasAuthorship W2547720907A5054799901 @default.
• W2547720907 hasAuthorship W2547720907A5057016594 @default.
• W2547720907 hasAuthorship W2547720907A5061357555 @default.
• W2547720907 hasAuthorship W2547720907A5061673554 @default.
• W2547720907 hasAuthorship W2547720907A5063772828 @default.
• W2547720907 hasAuthorship W2547720907A5070914037 @default.
• W2547720907 hasAuthorship W2547720907A5076752506 @default.
• W2547720907 hasAuthorship W2547720907A5078556050 @default.
• W2547720907 hasAuthorship W2547720907A5080348265 @default.
• W2547720907 hasAuthorship W2547720907A5086156844 @default.
• W2547720907 hasAuthorship W2547720907A5086803629 @default.
• W2547720907 hasAuthorship W2547720907A5088572719 @default.
• W2547720907 hasAuthorship W2547720907A5090764517 @default.
• W2547720907 hasBestOaLocation W25477209071 @default.
• W2547720907 hasConcept C118552586 @default.
• W2547720907 hasConcept C126322002 @default.
• W2547720907 hasConcept C142724271 @default.
• W2547720907 hasConcept C168563851 @default.
• W2547720907 hasConcept C170493617 @default.
• W2547720907 hasConcept C204787440 @default.
• W2547720907 hasConcept C27081682 @default.
• W2547720907 hasConcept C2778186239 @default.
• W2547720907 hasConcept C2778750930 @default.
• W2547720907 hasConcept C2781063702 @default.
• W2547720907 hasConcept C2781326671 @default.
• W2547720907 hasConcept C42219234 @default.
• W2547720907 hasConcept C71924100 @default.
• W2547720907 hasConceptScore W2547720907C118552586 @default.
• W2547720907 hasConceptScore W2547720907C126322002 @default.
• W2547720907 hasConceptScore W2547720907C142724271 @default.
• W2547720907 hasConceptScore W2547720907C168563851 @default.
• W2547720907 hasConceptScore W2547720907C170493617 @default.
• W2547720907 hasConceptScore W2547720907C204787440 @default.
• W2547720907 hasConceptScore W2547720907C27081682 @default.
• W2547720907 hasConceptScore W2547720907C2778186239 @default.
• W2547720907 hasConceptScore W2547720907C2778750930 @default.
• W2547720907 hasConceptScore W2547720907C2781063702 @default.

• next